AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that upon the recommendation of its external regulatory and clinical advisors, the Company will include additional patient tissue samples from its Phase 3 trials for p53 biomarker analyses to predict ADVEXIN efficacy to strengthen its U.S. and European regulatory filings. This recommendation was made by the advisors without knowledge of Introgen’s Phase 3 clinical trial results.
